SKEL fjárfestingafélag hf.: Buy-back Programme
The Annual General Meeting of SKEL fjárfestingafélag hf. held 9 March 2023 authorized the Board of Directors, pursuant to Article 55 of the Company Act No 2/1995, to purchase upto 10% of the company‘s shares on its behalf. The purpose of the program is to decrease the number of issued shares.
The Board of Directors of SKEL has on the basis of the mandate issued by the Annual General Meeting adopted a decision on the execution of a buy-back program. The aim is to buy back own shares for the maximum amount of 9.04% of issued shares, the total amount of the buy-back however not exceeding 500,000,000 ISK in total purchase price. SKEL now holds 18,518,518 own shares or 0.956% of issued shares.
The buy-back will be executed in stages, with the maximum amount of shares equivalent to 25% of the average daily trade in the company‘s shares on Nasdaq OMX Iceland for the previous 20 business days. The share price shall not exceed the highest price in the last independent trade or highest existing bid in the Nasdaq OMX Iceland trading venue, which ever is higher.
The buy-back program will start on Monday 18 September 2023 and remain in force until 31 December 2023 unless the conditions on the maximum amount will be met before that time.
Fossar fjárfestingarbanki hf. are managing the buy-back program and independently adopt all decisions on the timing of the purchase of shares.
The buy-back program will be executed in accordance with the Company Act No 2/1995 and the annex to the Regulation on insider information and market abuse No 630/1995. Notices on trading in own shares will be published no later than at the end of the seventh trading day following the purchase of shares.
For further information contact Magnús Ingi Einarsson, CFO of SKEL fjárfestingafélag hf., firstname.lastname@example.org.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
SkiStar Year-End Report September 2022-August 20233.10.2023 07:00:00 CEST | Press release
STABLE GROWTH IN TURNOVER – HIGH BOOKING RATE FOR THE WINTER Fourth Quarter Net sales for the fourth quarter increased by SEK 121 million (54 percent) to SEK 345 (224) million.Operating profit for the fourth quarter amounted to SEK -230 (-265) million, an improvement of SEK 35 million (13 percent).Capital gains from exploitation operations included SEK 63 (-4) million.Earnings per share before and after dilution amounted to SEK -2.64 (-2.70). Full Year Net sales for the full year were SEK 4,281 (4,092) million, an increase of SEK 189 million (5 percent).Operating profit for the full year decreased by SEK 280 million (32 percent) to SEK 604 (884) million.Earnings per share before and after dilution amounted to SEK 5.13 (8.50), a decrease of 40 percent.Capital gains from Property Development and Exploitation operations included SEK 75 (57) million.The Board proposes a dividend of SEK 2.60 (3.00) per share, totalling SEK 204 (235) million. The dividend represents 51 (36) percent of the Gr
NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society3.10.2023 07:00:00 CEST | Press release
NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society NMD Pharma will show the first ever clinical proof-of-mechanism for the novel concept of ClC-1 inhibition with NMD670 in treatment of neuromuscular diseases demonstrated in patients with myasthenia gravis The data provides clinical validation of the ability of CIC-1 inhibition to restore neuromuscular function leading to clinically meaningful effects with a single dose of NMD670This data has been instrumental in the design ofthe recently initiated Phase II clinical trial of NMD670 in patients with type 3 spinal muscular atrophy Aarhus, Denmark,3October2023 – NMD Pharma A/S, a clinical-stage biotech company developing first-in-class, small molecule ClC-1 inhibitors directly targeting muscle function within neuromuscular disorders, today announces that it will present data from a Phase I/IIa clinical trial of NMD670 in patients wit
“BEYOND THE EXPECTED”: SIKA LAUNCHES NEW GROWTH STRATEGY 2028 WITH MORE AMBITIOUS TARGETS3.10.2023 07:00:00 CEST | Press release
Ad Hoc Announcement Pursuant to Article 53 of the SIX Exchange Regulation Listing Rules “BEYOND THE EXPECTED”: SIKA LAUNCHES NEW GROWTH STRATEGY 2028 WITH MORE AMBITIOUS TARGETS At today’s Capital Markets Day in Zurich, Sika presents its new Strategy 2028, “Beyond the Expected”, which builds on the company’s successful growth model. The roadmap leverages on Sika’s strong market position and innovation power and sets the course for an even stronger performance in the years to come. The annual growth target will be lifted to 6-9% in local currencies and profitability target will be increased to an EBITDA margin of 20-23%. The new growth strategy is based on the four pillars market penetration, innovation & sustainability, acquisitions, as well as people & culture and includes a balanced set of financial and non-financial targets. Furthermore, Sika reports a strong sales growth year to date (January to August 2023) of +12.2%. Thomas Hasler, CEO: “Beyond the Expected – that’s what Sika sta
SkiStar Bokslutskommuniké september 2022-augusti 20233.10.2023 07:00:00 CEST | Pressemelding
STABIL OMSÄTTNINGSTILLVÄXT – HÖGT BOKNINGSLÄGE TILL VINTERN Fjärde kvartalet Nettoomsättningen för det fjärde kvartalet ökade med 121 MSEK, 54 procent, till 345 MSEK (224).Rörelseresultatet för det fjärde kvartalet uppgick till -230 MSEK (-265), vilket är en förbättring med 35 MSEK, 13 procent.Reavinster från exploateringsverksamheten ingick med 63 MSEK (-4).Resultat per aktie före och efter utspädning uppgick till -2,64 SEK (-2,70). Helåret Nettoomsättningen för helåret ökade med 189 MSEK, 5 procent, till 4 281 MSEK (4 092).Rörelseresultatet för helåret minskade med 280 MSEK, 32 procent, till 604 MSEK (884).Resultat per aktie före och efter utspädning uppgick till 5,13 SEK (8,50), vilket är en minskning med 40 procent.Reavinster från Fastighetsutvecklings- och exploateringsverksamheten ingick med 75 MSEK (57).Styrelsen föreslår en vinstutdelning om 2:60 SEK (3:00) per aktie, motsvarande totalt 204 MSEK (235). Utdelningen utgör 51 procent (36) av koncernens vinst efter skatt. Väsentlig
Technicolor Creative Studios: Business Update and First Half 2023 Financial Results2.10.2023 21:55:38 CEST | Press release
CORPORATE PRESS RELEASE Technicolor Creative StudiosBusiness Update and First Half 2023Financial Results PARIS (FRANCE), OCTOBER 2,2023 – Technicolor Creative Studios (Euronext Paris: TCHCS) (the “Company”) today provided business update and announced its first half 2023 financial results1. Acceleration of the transformation plan to drive the recovery of the business Impact of strikes in Hollywood andunfavourable macroeconomic environment led to reduction of activity withlower financial and operational performancefor thefirst half 2023Renewed confidence from majority shareholders and lenders with:An additional €30 million of new money injection to address liquidity needs A proposed tender offer (“offre publique d’achat simplifiée”)at a price of 1,63 euro per share, dividends included,to beinitiated by a large majority of shareholders and lenders (holding 94,82% of the capital) acting in concert in view of proceeding to a mandatory squeeze outto achieve delisting of Technicolor Creative